Patents Assigned to APTARION biotech AG
-
Patent number: 12188021Abstract: The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5? AUGn1GGUGKUn2n3RGGGHUGUKGGGn4Gn5CGACGCA 3? [SEQ ID NO: 61], wherein n1 is U or dU, n2 is G or dG, n3 is A or dA, n4 is U or dU, n5 is U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2?-deoxyribonucleotides.Type: GrantFiled: November 7, 2022Date of Patent: January 7, 2025Assignee: APTARION biotech AGInventors: Kai Hohlig, Axel Vater, Klaus Buchner, Christian Maasch, Sven Klussmann
-
Publication number: 20240384275Abstract: The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5? AUGn1GGUGKUn2n3RGGGHUGUKGGGn4Gn5CGACGCA 3?[SEQ ID NO: 61], wherein n1 is U or dU, n2 is G or dG, n3 is A or dA, n4 is U or dU, n5 is U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2?-deoxyribonucleotides.Type: ApplicationFiled: November 7, 2022Publication date: November 21, 2024Applicant: APTARION biotech AGInventors: Kai Hohlig, Axel Vater, Klaus Buchner, Christian Maasch, Sven Klussmann
-
Patent number: 11634741Abstract: The present invention is related to a method for adding one or more L-nucleotides to the 3?end of a first L-nucleic acid, wherein the method comprises the step of reacting the one or more L-nucleotides with the first L-nucleic acid in the presence of a protein comprising a mutant enzymatic activity exhibiting moiety, wherein the enzymatic activity is capable of adding one or more L-nucleotides to the 3? end of the first L-nucleic acid, wherein the mutant enzymatic activity exhibiting moiety comprises an amino acid sequence, wherein the amino acids of the amino acid sequence are D-amino acids, wherein the mutant enzymatic activity exhibiting moiety is a variant of an enzymatic activity exhibiting moiety, wherein the enzymatic activity exhibiting moiety consists of an amino acid sequence according to SEQ ID NO: 15 and wherein the amino acids of the amino acid sequence according to SEQ ID NO: 15 are D-amino acids, wherein the amino acid sequence of the mutant enzymatic activity exhibiting moiety differs from theType: GrantFiled: November 20, 2014Date of Patent: April 25, 2023Assignee: Aptarion biotech AGInventors: Andreas Pech, Florian Jarosch, Michael Jahnz, Sven Klussmann, Ralf David
-
Patent number: 11492625Abstract: The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5? AUGn1GGUGKUn2n3RGGGHUGUKGGGn4Gn5CGACGCA 3? [SEQ ID NO: 61], wherein n1 is U or dU, n2 is G or dG, n3 is A or dA, n4 is U or dU, n5 is U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2?-deoxyribonucleotides.Type: GrantFiled: March 15, 2020Date of Patent: November 8, 2022Assignee: APTARION biotech AGInventors: Kai Hohlig, Axel Vater, Klaus Buchner, Christian Maasch, Sven Klussmann
-
Publication number: 20210403913Abstract: The present invention is related to an L-nucleic acid molecule capable of binding to human CXCL8, wherein the L-nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5?-GG A AGU ACGUGGA AAGCCRA(Xu)RAGUGUGUCCCG-3? [SEQ. ID. NO: 27], wherein Xu is U or absent.Type: ApplicationFiled: November 12, 2019Publication date: December 30, 2021Applicant: Aptarion Biotech AGInventors: Kai Hohlig, Axel Vater, Werner Purschke, Dirk Zboralski, Christian Maasch
-
Publication number: 20210163946Abstract: The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5? AUGn1GGUGKUn2n3RGGGHUGUKGGGn4Gn5CGACGCA 3? [SEQ ID NO: 61], wherein n1 is U or dU, n2 is G or dG, n3 is A or dA, n4 is U or dU, n5 is U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2?-deoxyribonucleotides.Type: ApplicationFiled: March 15, 2020Publication date: June 3, 2021Applicant: Aptarion Biotech AGInventors: Kai Hohlig, Axel Vater, Klaus Buchner, Christian Maasch, Sven Klussmann
-
Patent number: 11015178Abstract: The present invention is related to a method for adding one or more L-nucleotides to the 3? end of a first L-nucleic acid, wherein the method comprises the step of reacting the one or more L-nucleotides with the first L-nucleic acid in the presence of a protein comprising an enzymatic activity exhibiting moiety, wherein the enzymatic activity is capable of adding one or more L-nucleotides to the 3? end of the first L-nucleic acid.Type: GrantFiled: December 5, 2017Date of Patent: May 25, 2021Assignee: APTARION biotech AGInventors: Andreas Pech, Ralf David, Florian Jarosch, Michael Jahnz, Sven Klussmann